Mobile

A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate ch...

Update Il y a 4 ans
Reference: EUCTR2006-000418-20

A 4-week randomized, double-blind, placebo controlled, parallel group, phase II study to assess the efficacy and safety of gefitinib tablets, 250 mg once daily (OD), in adult patients with moderate chronic obstructive pulmonary disease (COPD)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate the efficacy of gefitinib tablets, 250 mg once daily (OD) on symptoms, mainly cough and sputum production, in patients with Chronic Obstructive Pulmonary Disease (COPD) compared to placebo during a 4-week treatment period

Inclusion criteria

  • Moderate Chronic Obstructive Pulmonary Disease (COPD)

Links